Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration

Completed · Not applicable

Conditions studied: Exudative Macular Degeneration, Diabetic Macular Edema

In brief

The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.

Key facts

Study ID

NCT01473251

Run by

Vitreo-Retinal Associates, Michigan

People needed

16

Starts

2011-11-01

Expected to finish

2014-04-01

Last updated by the study team

2014-12-17

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female age 18 to 85 with diabetes and hemoglobin A1C </= 10, or exudative macular degeneration.
• Diabetic macular edema with average retinal thickness central subfield >/= 290um.

You may not qualify if…

• Macular atrophy/fibrosis.
• Ocular anti-VEGF treatment within 3 months.
• Treatment with topical or oral carbonic-anhydrase inhibitor within one month
• Laser photocoagulation within 3 months (diabetic cohort)

Where it is running

• Vitreo-Retinal Associates — Grand Rapids, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.